Apogee Therapeutics (NASDAQ:APGE) Price Target Raised to $125.00

Apogee Therapeutics (NASDAQ:APGE) had its target price hoisted by equities researchers at Citigroup from $95.00 to $125.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Citigroup’s target price suggests a potential upside of 69.74% from the company’s current price.

APGE has been the topic of several other reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Apogee Therapeutics in a research report on Wednesday, January 21st. Deutsche Bank Aktiengesellschaft started coverage on Apogee Therapeutics in a research report on Tuesday, December 9th. They issued a “buy” rating and a $103.00 target price for the company. Wolfe Research initiated coverage on shares of Apogee Therapeutics in a research report on Wednesday, January 7th. They set a “peer perform” rating on the stock. Truist Financial began coverage on shares of Apogee Therapeutics in a research note on Tuesday, March 17th. They set a “hold” rating and a $83.00 price target on the stock. Finally, Royal Bank Of Canada lowered their price objective on shares of Apogee Therapeutics from $83.00 to $82.00 and set a “sector perform” rating for the company in a report on Monday, March 2nd. Three equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $110.43.

Apogee Therapeutics Stock Down 7.1%

NASDAQ:APGE traded down $5.60 during midday trading on Tuesday, hitting $73.64. The company had a trading volume of 502,887 shares, compared to its average volume of 1,017,393. The company has a market capitalization of $5.12 billion, a PE ratio of -17.40 and a beta of 1.39. Apogee Therapeutics has a 52-week low of $26.20 and a 52-week high of $84.56. The stock’s fifty day moving average price is $71.28 and its 200-day moving average price is $63.70.

Apogee Therapeutics (NASDAQ:APGE) last released its quarterly earnings results on Monday, March 2nd. The company reported ($1.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.02. As a group, research analysts forecast that Apogee Therapeutics will post -3.09 earnings per share for the current year.

Insider Activity

In other news, CEO Michael Thomas Henderson sold 20,000 shares of the business’s stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $74.78, for a total value of $1,495,600.00. Following the completion of the sale, the chief executive officer owned 1,152,987 shares of the company’s stock, valued at approximately $86,220,367.86. The trade was a 1.71% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Carl Dambkowski sold 5,500 shares of the firm’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $71.06, for a total value of $390,830.00. Following the transaction, the insider owned 209,773 shares in the company, valued at approximately $14,906,469.38. The trade was a 2.55% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 1,839,700 shares of company stock valued at $140,118,083. Insiders own 42.77% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in APGE. Rockefeller Capital Management L.P. purchased a new position in shares of Apogee Therapeutics in the fourth quarter worth $25,000. ANTIPODES PARTNERS Ltd grew its holdings in Apogee Therapeutics by 41.2% in the 3rd quarter. ANTIPODES PARTNERS Ltd now owns 843 shares of the company’s stock worth $33,000 after acquiring an additional 246 shares during the last quarter. Los Angeles Capital Management LLC bought a new stake in Apogee Therapeutics in the 4th quarter worth $37,000. Quantbot Technologies LP purchased a new position in shares of Apogee Therapeutics in the third quarter valued at about $96,000. Finally, Seven Fleet Capital Management LP purchased a new position in shares of Apogee Therapeutics in the fourth quarter valued at about $136,000. Institutional investors own 79.04% of the company’s stock.

Apogee Therapeutics News Roundup

Here are the key news stories impacting Apogee Therapeutics this week:

• Positive Sentiment: Positive 52‑week Phase 2 APEX data for zumilokibart showed durable maintenance and deepening of responses (EASI‑75 maintenance ~75% Q3M and ~85% Q6M; strong vIGA results), supporting the drug’s clinical profile and commercial potential. GlobeNewswire release
• Positive Sentiment: Multiple sell‑side upgrades and large price‑target increases (Guggenheim to $160, Canaccord to $130, BTIG reaffirmed $137) signal renewed analyst conviction and imply significant upside versus pre‑news levels. Benzinga
• Neutral Sentiment: Investor commentary and analysis (Seeking Alpha slides/transcript and valuation notes) highlight durable efficacy, convenient infrequent dosing (Q3M/Q6M) and a solid cash position — these support the bull case but also note valuation/near‑term catalysts and M&A considerations. Seeking Alpha
• Neutral Sentiment: Company hosted/announced a conference call and slide deck to discuss the 52‑week data — useful for investors wanting detail on durability, safety and positioning versus competitors. Yahoo/Conference Call
• Negative Sentiment: Apogee announced a proposed $300M underwritten public offering (with a 30‑day upsize option), which introduces near‑term dilution risk and commonly puts downward pressure on the stock while the offering is live. This is the most likely proximate cause of the intraday pullback. GlobeNewswire offering notice
• Neutral Sentiment: Reported short‑interest data in the feed is inconsistent/insignificant (shows 0 shares), so it provides no clear signal on bearish positioning. Short interest note

About Apogee Therapeutics

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.